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Abstract
Background
Persistent pain is a challenging clinical problem after breast cancer treatment. After surgery,
inflammatory pain and nociceptive input from nerve injury induce central sensitization which
may play a role in the genesis of persistent pain. Using quantitative sensory testing, we
tested the hypothesis that adding COX-2 inhibition to standard treatment reduces hyperal-
gesia after breast cancer surgery. A secondary hypothesis was that patients developing per-
sistent pain would exhibit more postoperative hyperalgesia.
Methods
138 women scheduled for lumpectomy/mastectomy under general anesthesia with paraver-
tebral block were randomized to COX-2 inhibition (2x40mg parecoxib on day of surgery,
thereafter 2x200mg celecoxib/day until day five) or placebo. Preoperatively and 1, 5, 15
days and 1, 3, 6, 12 months postoperatively, we determined electric and pressure pain toler-
ance thresholds in dermatomes C6/T4/L1 and a 100mm VAS score for pain. We calculated
the sum of pain tolerance thresholds and analyzed change in these versus preoperatively
using mixed models analysis with factor medication. To assess hyperalgesia in persistent
pain patients we performed an additional analysis on patients reporting VAS>30 at 12
months.
Results
48 COX-2 inhibition and 46 placebo patients were analyzed in a modified intention to treat
analysis. Contrary to our primary hypothesis, change in the sum of tolerance thresholds in
the COX-2 inhibition group was not different versus placebo. COX-2 inhibition had an effect
on pain on movement at postoperative day 5 (p<0.01). Consistent with our secondary
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hypothesis, change in sum of pressure pain tolerance thresholds in 11 patients that devel-
oped persistent pain was negative versus patients without pain (p<0.01) from day 5 to 1
year postoperatively.
Conclusions
Perioperative COX-2 inhibition has limited value in preventing sensitization and persistent
pain after breast cancer surgery. Central sensitization may play a role in the genesis of per-
sistent postsurgical pain.
Introduction
Persistent pain after surgery is a significant clinical problem which affects 10 to 50 percent of
patients [1]. Chronic pain treatments are effective in reducing pain in only about 30 percent of
patients with such persistent pain [2]. In breast cancer surgery similar outcomes are reported,
with around 40 percent of patients suffering from persistent pain one year after surgery [3, 4].
These results are not surprising in view of the complexity of persistent pain and current empir-
ical symptom-based pain management approaches. Further improvement in persistent and
chronic pain management will likely depend on the development of more mechanism-based
approaches [5, 6].
A key insight from fundamental pain research is that ongoing nociceptive input alters sub-
sequent sensory processing by the nervous system [7]. Surgical nociception results in postoper-
ative hyperalgesia via pronociceptive changes in central nervous system processing. Such
‘central sensitization’ occurs via two mechanisms, namely damage to tissues and to nerves,
with the former acting more via humoral biochemical products of tissue inflammation, and
the latter more via neuronal mechanisms [7]. Postoperative central sensitization and hyperal-
gesia not only lead to increased acute pain, they have also been linked to subsequent develop-
ment of chronic pain [8–13]. Preventing postoperative central sensitization may therefore
provide an attractive mechanism based approach to prevent persistent pain development, e.g.
by blocking nociceptive input or direct antihyperalgesic therapy [14–18].
Regional anesthesia is currently the best therapy to block surgical nociceptive input and may
protect partially against persistent pain development after surgery [19–21]. However, even with
paravertebral block around twenty-two percent of women undergoing breast cancer surgery
suffer from persistent pain six months after surgery [22, 23]. To further improve management
of surgical pain it would be useful to understand the effect of adding inhibition of the inflamma-
tory component of sensitization, e.g. by providing perioperative cyclooxygenase-2 (COX-2)
inhibition [24–26] in addition to blockade of neuronal nociceptive input. COX-2 inhibitors
interfere with prostaglandin production [27] and may counteract central sensitization develop-
ment by inhibiting peripheral sensitization [27] and reducing nociceptive input. Additionally,
COX-2 inhibitors may prevent central sensitization by a central mechanism [24, 27].
The primary aim of this study was to assess the value of perioperatively inhibiting the
inflammatory component of sensitization added to block of neuronal nociceptive input on
central sensitization after surgery. A secondary aim was to assess the relationship between
hyperalgesia and persistent pain development at 12 months postoperatively. We studied these
aims in a randomized prospective controlled trial in women undergoing breast cancer surgery
under paravertebral blockade combined with perioperative COX-2 inhibition or placebo. We
hypothesized that:
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1. Adding COX-2 inhibition to standard maximal antinociceptive treatment (paravertabral
blockade) perioperatively would result in less widespread hyperalgesia as a sign of central
sensitization–and therefore less persistent pain–following surgery compared to a placebo-
supplemented group.
2. Patients who complained of persistent pain 12 months postoperatively would exhibit more
widespread hyperalgesia following surgery, than patients not complaining of persisting
pain.
Materials and Methods
We conducted a prospective, randomized, double blind, placebo-controlled, clinical trial at the
Bernhoven Hospital in Uden, the Netherlands, approved by the Ethical Committee on March
16th 2005 (nr: 2004/239, CMO region Arnhem-Nijmegen, Nijmegen, The Netherlands). All
participants provided written informed consent; the trial was registered with the Netherlands
Trial Register (NTR1793). Trial registration was not complete when subject recruitment had
begun. However, this was rectified and our trial was registered on May 3rd 2009. The authors
confirm that all ongoing and related trials for this drug/intervention are registered. The proto-
col for this trial and supporting CONSORT checklist are available as supporting information;
see S1 Checklist and S1 Protocol.
Patients
We included women scheduled for breast cancer surgery. Two dedicated breast surgeons per-
formed all surgeries. Surgery was by lumpectomy, total simple mastectomy or modified radical
mastectomy. Exclusion criteria were: previous breast surgery, planned immediate breast
reconstruction, chronic pain syndromes (e.g. fibromyalgia, osteoarthritis), regular analgesic
medication for 2 weeks preceding surgery, pre-existing central nervous system pathology (e.g.
stroke, dementia), conditions predisposing to neuropathy (e.g. diabetes mellitus, alcohol
abuse), inability to comply with testing procedures or to give informed consent, presence of
contra-indications to COX-2 therapy (including untreated hypertension, active or recent gas-
trointestinal ulceration) and contraindications to paravertebral blockade.
Randomization and treatment
After obtaining informed consent during an outpatient anesthesia visit, eligible patients were
randomized in a one-to-one ratio to receive perioperative COX-2 inhibition or placebo. A
pseudo-random code was computer generated for the randomization blocks that had a size of
six. Stratified random sampling ensured equal distribution of axillary lymph node dissections
over groups. The hospital pharmacy held the randomization scheme for the trial and supplied
parecoxib and celecoxib (active treatment) or placebo in blinded packages. Parecoxib is cur-
rently not FDA approved, but is widely available worldwide, including in the European Union
as the only injectable COX-2 specific inhibitor. The morning of surgery, patients received oral
midazolam premedication (7.5 mg). In the operating theatre, COX-2 inhibition group patients
received parecoxib 40 mg i.v. 30 minutes before surgery start. This injection was repeated 6
hours later. The postoperative morning, patients started celecoxib 200mg, continued to the
morning of day five postoperatively. The placebo group received placebo injections and tablets
according to the same regime. Medication was blinded, neither observers nor persons involved
in patient management were aware of patient assignment.
Hyperalgesia and Persistent Pain after Breast Cancer Surgery
PLOS ONE | DOI:10.1371/journal.pone.0166601 December 9, 2016 3 / 21
Anesthesia and analgesia
Paravertebral blockade was by standard technique (20 ml ropivacaine 0.75%). Before surgery,
local anaesthetic blockade was tested using pin-prick. Unsuccessful block, as defined by no
hypoalgesia to pinprick, led to patient exclusion. Patients received standardized general anaes-
thesia [28], (propofol 2–3 mg/kg, fentanyl 3 μg/kg, rocuronium 0.5 mg/kg, air/oxygen (40%),
sevoflurane) to achieve haemodynamic values within 20% of preoperative baseline. For proce-
dures longer than 45 minutes, further fentanyl supplementation (1 μg/kg) was permitted at 45
minutes and at further 45-minute intervals. No further myorelaxants were given and no antag-
onisation was performed. In the recovery room, initial analgesia consisted of piritramide as
soon as patients complained of pain, titrated to VAS3 by the recovery room nurse using 3
mg intravenous increments. Thereafter, standard postoperative analgesia consisted of a fixed
acetaminophen scheme (4 X 1g /day) together with on-demand tramadol (drops, maximum
300 mg/day) up to day 5 postoperatively.
Measurement protocols
Trained research personnel performed all testing in a standardized fashion in a quiet room. All
subjects underwent familiarization training with sensory testing before the study. Pain was
assessed via 100 mm visual analogue scores at rest (lying quietly in bed) and on movement
(immediately after sitting up on bed). For all postoperative pain scores, the patient was explic-
itly asked to report pain associated with surgery at that moment. At several time points patients
were asked to complete a quality of life questionnaire assessing surgery-related symptoms and
functional impairment.
Postoperative changes in pain sensitivity (hyperalgesia) were quantified using electric and
pressure pain tolerance thresholds. Electricity stimulates mainly cutaneous nerve endings [29],
bypassing nociceptors; pressure reveals deep tissue sensitivity (e.g. muscle), with only minimal
cutaneous contributions [30]. Thus electric pain tolerance thresholds mainly reflect cutaneous
sensitivity and pressure pain tolerance thresholds mainly reflect deep tissue sensitivity. Thresh-
olds were measured close to the affected breast and distant from the site of surgery to obtain
measures of secondary (peri-incisional) and spreading (or generalizing) hyperalgesia, respec-
tively. Pain modulation was assessed preoperatively via conditioned pain modulation (CPM)
paradigm [31]. At no time were patients or treating personnel aware of results of pain process-
ing tests.
Baseline demographic data, electric pain tolerance thresholds, pressure pain tolerance
thresholds and CPM were collected the preoperative afternoon. Pain scores, electric pain toler-
ance thresholds and pressure pain tolerance thresholds were collected 1, 5 and 15 days after
surgery and at 1, 3, 6 and 12 months after surgery.
Electric and pressure pain tolerance thresholds
Electric pain tolerance threshold testing was performed using an electric stimulation device
(QST-3; JNI, Aalborg, Denmark), delivering electrical tetanic stimulation (100 Hz, 0.2-ms
square waves, 0.1mA/s ramping rate) via self-adhesive skin electrodes 3 cm apart. A trained
research assistant operated the device and documented the value at which stimulation became
intolerable and was discontinued. Pain tolerance thresholds were determined three times and
the mean value was used. Pressure pain tolerance thresholds were assessed using a pressure
algometer (Somedic Sales AB, Horby, Sweden) with a 1.0 cm2 probe and a ramping rate of 50
kPa/s[28] until the patient did not accept a higher stimulus intensity. The electric pain toler-
ance thresholds were measured at each of the following sites on both the affected body side
and the contralateral side: Radial upper arm (C6 dermatome), mid-axillary line (T4
Hyperalgesia and Persistent Pain after Breast Cancer Surgery
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dermatome, 5–10 cm from incision, affected side) and iliac crest (L1 dermatome). The pressure
pain tolerance thresholds were measured bilaterally on the index finger (C6 dermatome), iliac
crest (L1 dermatome) and sternum in the midline (T4 dermatome). To avoid mass significance
and as a measure of central sensitization the sum of all the thresholds (SOT) across dermatomes
was calculated [14] for the electric thresholds and for the pressure thresholds. Postoperative
changes in SOTs were expressed as percentage changes compared to preoperative baseline.
Conditioned pain modulation (CPM) paradigm
The condition pain modulation paradigm tests the ability to generate descending inhibitory
modulation [31]. An electric pain threshold (test stimulus) was determined before and after a
cold pressor task (conditioning stimulus), and the CPM effect was determined as the relative
change (%) in electric pain threshold. For the cold pressor task the dominant hand was
immersed in ice-chilled water (1.0˚C ±0.3˚C) stirred by pump. The patient was told to remove
the hand from the water after two minutes of immersion–or sooner if the pain was considered
intolerable–and immersion time was noted. Immediately after the cold pressor task, the sub-
jects rated the pain experienced during the test by VAS for quality control purposes. Electric
pain thresholds were obtained in the L1 dermatome immediately before and after ice-water
immersion.
Quality of life
At baseline and 1, 3, 6, and 12 months post surgery patients filled out a quality of life question-
naire (Dutch version of the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-C30). The EORTC QLQ-C30 is internationally validated for
evaluating quality of life in daily living and symptoms and side effects related to different treat-
ment modalities [32]. The individual functional, symptom and quality of life (QOL) scales
were summated to create general sum scores [33]. We calculated symptom, functioning and
QOL sum scores from the EORTC questionnaires.
Outcome measures
The primary study outcomes are change in electric and pressure SOT after surgery vs. baseline
values. Secondary outcomes are VAS pain and EORTC symptom, functional and QOL sum
scores.
Power-analysis
Based on data from previous postoperative quantitative sensory testing studies by our group
[28, 34] we can expect electric pain tolerance thresholds in thoracic dermatomes five days after
surgery to be 8.1 mA (SD = 4.5 mA). Sample size calculation based on these data for Type 1
error (alpha) of 0.05 and power (beta) of 80% predicts ability to detect a clinically relevant
change in pain tolerance thresholds of one third with a sample size per group of 45 patients.
Assuming a drop-out rate of 20–25%, a sample size of n = 55 per group should suffice to detect
clinically relevant reductions of one-third in the pain tolerance threshold (vs. the other group)
at 5 days postoperatively.
Data and statistical analysis
Data were analyzed with Statistica (version 12.0, Statsoft, Tulsa, OK, USA), p<0.05 was con-
sidered significant. Results are expressed as mean ± 95% confidence interval. Postoperative
sums of thresholds were expressed as percentage change compared to preoperative baseline.
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Chi-squared tests and t-tests were used to assess differences between the treatment groups
regarding axillary lymph node dissection, type of surgery, duration of surgery, surgical compli-
cations, size of specimen removed, baseline electric SOT, baseline pressure SOT, baseline
CPM, baseline QOL-score, baseline functioning score and baseline symptom score.
Our main analysis was aimed at testing our primary hypothesis that perioperative COX-2
inhibition would result in less hyperalgesia as a sign of central sensitization following surgery
compared to a placebo-supplemented group. We performed mixed model analyses on change
in electric and pressure SOT, and on secondary outcomes VAS scores and EORTC sum scores
with fixed factors medication (COX-2 inhibition vs. placebo) and time, and subjects were
included as random factor. Preoperative CPM is reported in the literature as a predictor for
persistent postsurgical pain development and was included as covariate [35]. We performed a
(modified) intention to treat analysis, which included all patients that received at least one
dose of study drug (COX-2 inhibition or placebo) [36–39]. Post-hoc tests with Bonferroni cor-
rection were used to identify significant differences between medication groups or time levels
when a main or interaction effect for the factors was found. A two-sided p-value <0.05 was
considered significant for all tests.
To test our secondary hypothesis that patients developing persistent pain 12 months postop-
eratively would exhibit more hyperalgesia following surgery than patients not complaining of
persisting pain two groups were formed post hoc: patients with persistent pain 12 months post-
operatively (answering “yes” to the question:” do you have persistent pain due to your surgery”,
plus reporting pain at rest or on movement of>30 mm on VAS) or those without persistent
pain. The chosen cutoff score>30 mm VAS is widely used in the pain literature [40, 41], corre-
sponds to moderate or severe pain [42], and a 30 mm VAS difference is a relevant treatment dif-
ference [43, 44]. We performed additional mixed model analyses on SOTs, pain scores and
QOL scores to assess differences between these two groups. Post-hoc tests with Bonferroni cor-
rection were used to identify significant differences between patients with and without persis-
tent pain or time levels when a main or interaction effect for the factors was found.
Results
From October 2006 to December 2010 a total of 327 patients were screened for eligibility and
138 patients were randomized (Fig 1). There was relatively high exclusion rate due to treat-
ment failure (unsuccessful paravertebral block) in 5 patients and failure of the hospital phar-
macy to deliver study drugs to the operating room on time in 30 patients. 6 patients were
excluded because they were found not to be suffering from malignant disease after pathological
examination. 94 patients were analyzed in the modified intention to treat analyses. When we
compared demographics of excluded patients for mastectomy rate (32 vs. 28%, chi-squared
test p = 0.59) and age (56 ± 14 vs. 53 ± 10, unpaired t-test p = 0.27) we found them to be com-
parable to the analyzed groups.
There were no differences in baseline and demographic data between the placebo and
COX-2 inhibition group (Table 1). Surgical complications occurred in 5 patients in the placebo
group, consisting of hematomas that had to be drained in 3 patients, an abscess that had to be
drained, and a nipple granuloma that had to be removed operatively. One patient in the COX-
2 inhibition group developed an infected seroma that had to be drained. Because immediate
reconstruction was an exclusion criterion, there was only one patient (in the COX-2 inhibition
group) that underwent reconstruction by insertion of a tissue expander and subpectoral pros-
thesis implantation (495 cc, Mentor©, Minneapolis, MN, USA) in the year following the initial
breast cancer surgery. There were no harmful or unintended effects associated with COX-2
inhibition.
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Primary hypothesis: hyperalgesia and COX-2 inhibition
Electric and pressure SOT. Perioperative treatment with COX-2 inhibition was not asso-
ciated with postoperative differences in tolerance to electric or pressure stimulation (Fig 2 and
Table 2).
VAS scores. COX-2 inhibition did not affect VAS scores at rest but influenced VAS scores
on movement (Time x Medication: p = 0.02)–Fig 2 and Table 2. Post-hoc testing revealed that
COX-2 inhibition led to lower postoperative VAS score on movement only on postoperative
day 5.
Preoperative CPM. Covariate preoperative CPM significantly affected electric SOT
(p = 0.04), and showed a trend towards significance on pressure SOT (p = 0.06)–Table 2.
Impaired preoperative CPM was related to more negative postoperative change in sensitivity.
Of note, preoperative CPM did not influence postoperative VAS scores at rest or on movement.
EORTC sum scores. EORTC functioning, symptom and QOL score were comparable
between treatment groups (Fig 3 and Table 2).
Secondary hypothesis: persistent pain and hyperalgesia
Persistent postsurgical pain. Twelve months postoperatively 11 patients (13%) com-
plained of persistent pain with VAS>30 mm. Characteristics of patients that eventually would
develop persistent pain and patients free of pain are displayed in Table 3. Patients that would
eventually develop persistent pain had higher baseline pressure SOT and electric SOT.
Fig 1. Study enrollment and randomization.
doi:10.1371/journal.pone.0166601.g001
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Electric and pressure SOT. Patients in the persistent postsurgical pain group did not
exhibit postoperative hyperalgesia to electric stimulation, but were significantly more hyperal-
gesic postoperatively to pressure stimulation (Persistent pain: p<0.01)–Fig 4 and Table 2.
Post-hoc analysis revealed that persistent pain patients were hyperalgesic to pressure stimula-
tion versus patients not developing pain on day 5 and throughout the rest of the postoperative
year.
VAS scores. Persistent pain patients had significantly higher postoperative pain VAS
scores at rest (Persistent pain: p<0.01, Time x Persistent pain: p<0.01) and on movement
(Persistent pain: p =<0.01, Time x Persistent pain: p<0.01)–Fig 4 and Table 2. These differ-
ences existed at all early and late postoperative timepoints, except for VAS at rest on day 5.
Paravertebral blockade provided excellent postoperative pain relief in the patients not develop-
ing persistent postsurgical pain.
Preoperative CPM. Covariate preoperative CPM significantly affected electric SOT
(p = 0.03) and showed a trend towards significance on pressure SOT (p = 0.07)–Table 2.
Impaired preoperative CPM was related to more negative postoperative change in sensitivity.
Preoperative CPM did not influence postoperative VAS scores at rest or on movement.
EORTC sum scores. Patients in the persistent postsurgical pain group reported lower
functioning score (Persistent pain: p<0.01) and total QOL (Persistent pain: p<0.01), and
higher symptom score (Persistent pain: p<0.01, Time x Persistent pain: p<0.01)–Fig 5 and
Table 2. Lower functioning score was present at 3, 6 and 12 months postoperatively for persis-
tent pain patients. Persistent pain was associated with higher symptom score and lower total
QOL score at 1, 3, 6 and 12 months postoperatively.
Discussion
We assessed the value of inhibiting the inflammatory component of sensitization added to
blockade of neuronal nociceptive input (paravertebral blockade) on central sensitization
Table 1. Demographic data of patients receiving COX-2 inhibition and placebo medication.
COX-2 inhibition (n = 48) Placebo (n = 46) P-value
Age in years 51 ± 9 55 ± 11 0.09
Body Mass Index in kg/m2 26 ± 5 25 ± 4 0.46
All mastectomies in % 25 30 0.56
Modified radical mastectomy in % 15 9 0.57
Axillary lymph node dissection in % 35 39 0.71
Duration of surgery in minutes 48 ± 25 44 ± 20 0.39
Size of specimen removed in cm3 435 ± 747 437 ± 695 0.99
Surgical complications in % 2 11 0.08
Chemotherapy in % 35 43 0.42
Radiotherapy in % 67 50 0.10
Electric SOT in mA 59 ± 29 58 ± 20 0.86
Pressure SOT in kPa 3167 ± 1397 2797 ± 1102 0.16
CPM in % 40 ± 43 29 ± 35 0.19
Functioning score 82 ± 14 86 ± 12 0.14
Symptom score 11 ± 12 9 ± 7 0.34
QOL score 70 ± 23 76 ± 18 0.23
Data are mean ± sd, continuous data were compared using unpaired t-tests, binomial data using chi-squared tests. SOT, sum of thresholds, CPM,
conditioned pain modulation, QOL, quality of life.
doi:10.1371/journal.pone.0166601.t001
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(expressed as widespread hyperalgesia) and persistent pain after surgery in women undergoing
surgery for breast malignancy. Adding perioperative COX-2 inhibition to maximal anti-noci-
ceptive therapy had no impact on change in electric or pressure pain tolerance thresholds as a
measure of central sensitization after breast cancer surgery. COX-2 inhibition did lead to
lower pain scores on movement at postoperative day 5, but had no effect on later time points
and did not affect quality of life scores. Thus, our primary hypothesis was rejected.
We found that patients developing persistent postsurgical pain were significantly more
hyperalgesic to pressure both early after surgery (5 days) and throughout the rest of the year
(15 days to 12 months). Thus, our secondary hypothesis was confirmed. There was no differ-
ence in sensitivity to electric quantitative sensory testing. Patients with persisting pain 12
months postoperatively had more pain in the acute postoperative period (1, 5 and 15 days) and
Fig 2. Effect of medication on electric and pressure SOT and VAS scores. Panels A + B show mean change ± 95% CI of SOT versus baseline, panels C
+ D show the mean ± 95 CI of VAS scores at the different time points. *Different vs. baseline (Bonferroni adjusted p<0.05); †Different vs. COX-2 inhibition
(Bonferroni adjusted p<0.05). SOT, sum of thresholds, VAS, Visual Analogue Score.
doi:10.1371/journal.pone.0166601.g002
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Table 2. Results of the main and secondary analyses.
Main Analysis Secondary Analysis
Factor Medication Time x Medication CPM Persistent pain Time x Persistent pain CPM
Effect on electric SOT (P-value, effect size) 0.74, 4.42 0.52, N/A 0.04, 0.11 0.88, -9.56 0.37, N/A 0.03, 0.14
Pairwise comparisons (P-value, effect-size)
Day 1 N/A N/A
Day 5 N/A N/A
Day 15 N/A N/A
Month 1 N/A N/A
Month 3 N/A N/A
Month 6 N/A N/A
Month 12 N/A N/A
Effect on pressure SOT (P-value, effect size) 0.12, -7.93 0.99, N/A 0.06, 0.16 <0.01, -30.51 0.36, N/A 0.07, 0.17
Pairwise comparisons (P-value, effect-size)
Day 1 N/A 0.35, -12.68
Day 5 N/A 0.02, -30,96
Day 15 N/A <0.01, -34.97
Month 1 N/A <0.01, -47.09
Month 3 N/A 0.02, -30.95
Month 6 N/A <0.01, -41.47
Month 12 N/A 0.03, -30.51
Effect on VAS at rest (P-value, effect size) 0.47, -0.18 0.31, N/A 0.61, -0.01 <0.01, 18.97 <0.01, N/A 0.14, -0.03
Pairwise comparisons(P-value, effect-size)
Baseline N/A 0.57, 2.00
Day 1 N/A <0.01, 22.10
Day 5 N/A 0.05, 6.75
Day 15 N/A 0.03, 7.74
Month 1 N/A 0.02, 7.98
Month 3 N/A <0.01, 12.89
Month 6 N/A <0.01, 14.75
Month 12 N/A <0.01, 18.97
Effect on VAS on movement (P-value, effect size) 0.44, -0.28 0.02, N/A 0.70, 0.01 <0.01, 47.20 <0.01, N/A 0.73, 0.01
Pairwise comparisons (P-value, effect-size)
Baseline 0.92, -0.39 0.29, 5.34
Day 1 <0.01, -11.09 <0.01, 29.41
Day 5 0.75, -1.24 <0.01, 18.71
Day 15 0.35, 3.70 <0.01, 17.03
Month 1 0.12, -6.19 <0.01, 17.66
Month 3 0.98, -0.12 <0.01, 28.83
Month 6 0.71, -1.50 <0.01, 27.22
Month 12 0.95, -0.28 <0.01, 47.20
Effect on function score (P-value, effect size) 0.31, -0.52 0.48, N/A 0.39, 0.03 <0.01, -12.59 0.38, N/A 0.34, 0.04
Pairwise comparisons (P-value, effect-size)
Baseline N/A 0.19, -6.52
Month 1 N/A 0.06, -9.47
Month 3 N/A <0.01, -15.91
Month 6 N/A <0.01, -13.29
Month 12 N/A 0.02, -12.59
Effect on symptom score (P-value, effect size) 0.30, -0.25 0.21, N/A 0.73, -0.01 <0.01, 16.69 <0.01, N/A 0.41, -0.02
(Continued )
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the rest of the year (1, 3 and 6 months). Total QOL and functioning scores were lower in per-
sistent pain patients and symptom score was higher vs. patients not developing persisting pain.
Our study describes the effects of perioperative COX-2 inhibition on postoperative sensiti-
zation of pain processing in a long-term prospective and longitudinal trial. Regarding persis-
tent pain (but not hyperalgesia) after breast surgery some data are available regarding
perioperative COX-2 inhibition. Romundstad et al. [45] found no difference versus placebo of
a single peri-operative dose of 40 mg parecoxib on persistent pain one year after surgery in
patients undergoing augmentation mammaplasty. Another trial [46] reported no impact on
pain six months postoperatively of ibuprofen 400 mg before mastectomy plus four additional
doses afterwards.
Surgical tissue damage is associated with prostanoid production [47]. This release, involv-
ing COX-2 induction, occurs peripherally and in the central nervous system [24]. Peripheral
release of prostanoids (PGE-2, PGI-2) sensitizes peripheral nociceptors. Centrally synthesized
PGE-2, by increased COX-2-expression, leads directly to central sensitization of the pain sys-
tem [24, 48, 49]. COX-2 inhibitors interfere with both the peripheral and the central prosta-
glandin production [27]. Therefore, perioperative inhibition of COX-2 was expected to
ameliorate central sensitization and to increase pain thresholds, by both inhibiting peripheral
nociceptive input and by inhibiting direct central sensitization under influence of prostaglan-
dins. We did not observe this expected difference, suggesting that perioperative COX-2 induc-
tion and inflammation subsequent to tissue damage may be of little importance in inducing
postoperative central sensitization. Interestingly, a small recent trial with parecoxib failed to
induce a difference in pressure pain tolerance thresholds in CPRS patients outside the surgical
context [50].
The generalized pressure hyperalgesia detected in this study suggests that persistent central
sensitization is an important process in persisting pain development after surgery. Other quan-
titative sensory testing studies have assessed pain processing in women with persistent pain at
single time-points after breast cancer surgery. These studies confirm the widespread mechani-
cal hyperalgesia we observed [51, 52]. Others have demonstrated enhanced sensitivity to
Table 2. (Continued)
Main Analysis Secondary Analysis
Factor Medication Time x Medication CPM Persistent pain Time x Persistent pain CPM
Pairwise comparisons (P-value, effect-size)
Baseline N/A 0.24, 4.08
Month 1 N/A <0.01, 9.56
Month 3 N/A <0.01, 16.37
Month 6 N/A <0.01, 13.05
Month 12 N/A <0.01, 16.69
Effect on QOL score (P-value, effect size) 0.28, 0.04 0.57, N/A 0.53, 0.02 <0.01, -14.14 0.14, N/A 0.34, 0.03
Pairwise comparisons (P-value, effect-size)
Baseline N/A 0.14, -6.13
Month 1 N/A 0.02, -9.56
Month 3 N/A <0.01, -15.55
Month 6 N/A <0.01, -12.28
Month 12 N/A <0.01, -14.14
SOT, sum of thresholds, VAS, vusual analogue scale, QOL, quality of life. P-values for post-hoc test were adjusted for multiple testing using Bonferroni
correction.
doi:10.1371/journal.pone.0166601.t002
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electrical and thermal stimulation [53, 54], further supporting the presence of central sensitiza-
tion in persistent pain after breast cancer treatment. Recently, Andersen et al. found a relation-
ship between sensory disturbances and pain one week after surgery for breast cancer [55].
Hyperalgesia has also been reported 5 days after back surgery [56] and early postoperative
hyperalgesia has been linked to persistent pain development in smaller studies after abdominal
surgery [57, 58]. Hyperalgesia in the postoperative period is likely to be expressed as increased
pain experience, which we found for both VAS at rest and on movement. A significant rela-
tionship between early postoperative pain and persistent pain has previously been reported for
breast cancer surgery [13] and other interventions including cholecystectomy [8, 9], groin her-
nia repair [10] and thoracic surgery [12].
We observed a relatively low incidence of persistent postsurgical pain following surgery
(13%) compared to other less recent studies (25 to 60%)[59]. Maximal peri-operative blockade
of neuronal nociceptive input (paravertebral blockade), but also identification and attention to
sparing intercostobrachial and other nerves during lymph node dissection in the present study
[22], may explain the low incidence of persistent pain.
Implications
Our results indicate that the role of COX-2 and inflammation in the genesis of postoperative
hyperalgesia may be less important than that of neuronally mediated nociceptive input. Add-
ing perioperative COX-2 inhibition to maximal neuronal anti-nociceptive therapy (paraver-
tebral blockade) appears of limited clinical value in preventing postoperative hyperalgesia or
persistent pain.
Fig 3. Effects of medication on EORTC function, symptom and QOL sum scores. Panels A-C show the
mean ± 95% CI at the different time points. No difference between treatment groups at any time (all p>0.05).
QOL, quality of life.
doi:10.1371/journal.pone.0166601.g003
Table 3. Baseline characteristics of patients that eventually developed persistent and patients without pain.
With/Without persistent postsurgical pain With persistent pain (n = 11) Without persistent pain (n = 83) P-value
Age in years 53 ± 7 54 ± 10 0.79
Body mass index in kg/m2 27 ± 7 26 ± 4 0.37
All mastectomies in % 36 27 0.53
Modified radical mastectomy in % 27 8 0.17
Axillary lymph node dissection in % 54 36 0.23
Duration of surgery in minutes 46 ± 22 53 ± 27 0.34
Size of specimen removed in cm3 508 ± 872 459 ± 741 0.84
Surgical complications in % 9 6 0.70
Chemotherapy in % 45 39 0.66
Radiotherapy in % 64 60 0.82
Electric SOT in mA 81 ± 37 56 ± 22 <0.01
Pressure SOT in kPa 4114 ± 1416 2821 ± 1224 <0.01
CPM in % 28 ± 56 33 ± 33 0.65
Functioning score 78 ± 16 85 ± 13 0.12
Symptom score 14 ± 12 9 ± 9 0.20
QOL score 80 ± 13 87± 11 0.09
Data are mean ± sd, continuous data were compared using unpaired t-tests, binomial data using chi-squared tests. SOT, sum of thresholds, QOL, quality of
life, CPM, conditioned pain modulation.
doi:10.1371/journal.pone.0166601.t003
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Despite all patients receiving maximal neuronal anti-nociceptive therapy in the form of
paravertebral blockade, 13% of patients still developed persistent pain postoperatively. These
patients showed widespread hyperalgesia to pressure in the acute postoperative period and the
rest of the year and would seem to be relatively resistant to current therapeutic interventions.
Future studies should further explore causes of developing early and persistent postoperative
hyperalgesia, possibly an important process during persistent pain development.
Clinically, the fact that persistent pain patients showed more widespread hyperalgesia to
pressure in the acute postoperative period means that peri-operative monitoring using quanti-
tative sensory testing should be able to identify patients at risk of developing persistent post-
surgical pain, possibly allowing for targeted antihyperalgesic treatment.
There is increasing interest in the potential for perioperative quantitative sensory testing to
predict persistent postsurgical pain. A relationship between peri-operative quantitative sensory
Fig 4. Electric and pressure SOT and VAS scores in persistent pain patients versus women without pain. Panels A + B show mean change ± 95% CI
of SOT versus baseline, panels C + D show the mean ± 95% CI of VAS scores at the different time points. *Different vs. baseline (Bonferroni adjusted
p<0.05); † Different vs. No persistent pain (Bonferroni adjusted p<0.05). SOT, sum of thresholds, VAS, Visual Analogue Score.
doi:10.1371/journal.pone.0166601.g004
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testing measures and persistent pain has thus far been shown in only a limited number of stud-
ies. These studies demonstrated an association between persistent postsurgical pain and preop-
erative measures of widespread pain sensitization, such as pressure pain thresholds [60–63].
However most of these studies were conducted in the context of orthopedic joint surgery and
represent a very different patient population. In the orthopedic population patients have often
suffered from ongoing pain and nociceptive input for a prolonged time preoperatively, which
may have lead to sensitized central pain processing even before surgery. Conversely, patients
undergoing surgery for breast cancer are highly unlikely to have suffered from significant pain
preoperatively and are thus unlikely to express centrally sensitized pain processing preopera-
tively. Future studies should clarify which quantitative sensory measurement at which time
point can best predict persistent pain in the breast cancer population.
Prediction and possible interventions targeting persistent pain after breast cancer surgery
are especially relevant given the poorer function scores and QOL we found with persistent
pain after breast cancer surgery. Furthermore, persistent pain after breast cancer surgery is
increasing in prevalence due to increased survival after breast cancer [59].
Methods and limitations
We chose quantitative sensory testing measures as the main outcome measures because we
intended to conduct a study investigating relations between COX-2 inhibition, hyperalgesia
development and persistent pain after surgery. Pressure quantitative sensory testing detects
hyperalgesia of deep tissues such as muscle as a manifestation of central sensitization [30], and
is considered a clinically robust and reliable measurement [64]. Electric quantitative sensory
testing stimulates peripheral cutaneous nerve endings bypassing peripheral nociceptors in skin
and is sensitive to local and descending modulation [29]. These characteristics may explain
why we found differences in pressure tolerance thresholds–but not in electric tolerance thresh-
olds–in persistent pain patients.
We measured electric and pressure pain tolerance thresholds at multiple topographic sites.
Others have advocated extensive multimodal quantitative sensory testing protocols [65]. These
protocols permit quantification of several different aspects of hyperalgesia, without, however,
achieving testing altered sensitivity at multiple sites, and are time-consuming. We chose our
battery of tests for its suitability for implementation into clinical practice. This testing protocol
generally lasts about 30 minutes and is well-accepted by patients with good reproducibility
(within 20%)[66].
Two limitations pertain to this study. First, we were unable to include some patients in the
modified intention to treat analysis due to treatment failure, and had to exclude some patients
due to an incorrect initial diagnosis. However, we achieved the group size we calculated
beforehand to deliver sufficient power to detect a 30% difference from baseline and the ana-
lyzed treatment groups were comparable for baseline characteristics. A second limitation was
the small number of patients developing pain 12 months postoperatively. A larger study popu-
lation and thus a larger group of pain patients might have provided more insight into the def-
erential characteristics of persistent pain patients vs. patients not suffering from pain, even
though we were able to detect several significant differences between the groups that we
analyzed.
Fig 5. EORTC function, symptom and QOL sum scores in persistent pain patients versus patients
with no pain. Panels A-C show the mean ± 95 CI at the different time points. *Different vs. baseline
(Bonferroni adjusted p<0.05); † Different vs. No persistent pain (Bonferroni adjusted p<0.05). QOL, quality of
life.
doi:10.1371/journal.pone.0166601.g005
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Conclusions
In conclusion, we found that adding perioperative COX-2 inhibition to current maximal anti-
nociceptive therapy (paravertebral blockade) has no significant impact on central sensitization,
persistent pain and QOL in the year following breast cancer surgery. Patients that developed
persistent pain after breast cancer surgery were significantly more hyperalgesic, had higher
pain scores and lower QOL throughout the year following surgery. Sensitization early after
surgery may play a role in the genesis of persistent pain after breast cancer surgery and periop-
erative monitoring using quantitative sensory testing may be able to identify patients at risk of
developing persistent pain.
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